GW Pharmaceuticals

Our vision is to be the global leaders in prescription cannabinoid medicines, through the rapid cost-effective development of pharmaceutical products which address clear unmet needs.
GW is developing a portfolio of cannabinoid medicines, including Sativex for the treatment of MS spasticity and cancer pain, and Epidiolex for the treatment of childhood epilepsy.

Company Growth (employees)
Type
Public
HQ
Histon, GB
Founded
1998
Size (employees)
496 (est)
GW Pharmaceuticals was founded in 1998 and is headquartered in Histon, GB

GW Pharmaceuticals Office Locations

GW Pharmaceuticals has offices in Histon, London and Carlsbad
Histon, GB (HQ)
Vision Park
Carlsbad, US
210 5800 Armada Dr
London, GB
1 Cavendish Pl

GW Pharmaceuticals Data and Metrics

GW Pharmaceuticals Financial Metrics

GW Pharmaceuticals's revenue was reported to be £10.3 m in FY, 2016 which is a 64% decrease from the previous period.
GBP

Revenue (FY, 2016)

10.3 m

Revenue growth (FY, 2015 - FY, 2016), %

(64%)

Gross profit (FY, 2016)

7.6 m

Gross profit margin (FY, 2016), %

74%

Net income (FY, 2016)

(63.7 m)

Market capitalization (25-Jul-2017)

2.9 b

Closing share price (25-Jul-2017)

115.2

Cash (30-Sep-2016)

374.4 m
GW Pharmaceuticals's current market capitalization is $2.9 b.
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

27.3 m30 m28.5 m10.3 m

Revenue growth, %

10%(5%)(64%)

Cost of goods sold

1.3 m2.1 m2.6 m2.7 m

Gross profit

26 m28 m25.9 m7.6 m

Gross profit Margin, %

95%93%91%74%

Pre tax profit

(19.6 m)(57.1 m)(86.2 m)

Net Income

(14.7 m)(44.6 m)(63.7 m)
GBPFY, 2014FY, 2015FY, 2016

Cash

164.5 m234.9 m374.4 m

Accounts Receivable

612 k373 k778 k

Current Assets

176.4 m255.1 m404.5 m

PP&E

11.9 m29.2 m42.8 m

Goodwill

5.2 m5.5 m5.8 m

Total Assets

193.5 m289.7 m453.2 m

Accounts Payable

2.3 m3.8 m3.4 m

Current Liabilities

17.3 m27.8 m35 m

Total Liabilities

34.9 m44.5 m54.7 m

Retained Earnings

(14.7 m)(44.6 m)(63.7 m)

Total Equity

158.6 m245.3 m398.5 m

Financial Leverage

1.2 x1.2 x1.1 x
GBPFY, 2014FY, 2015FY, 2016

Cash From Operating Activities

(12.6 m)(46.5 m)(84.6 m)

Cash From Financing Activities

144.3 m128.4 m206.8 m

Income Taxes Paid

4.9 m12.5 m22.5 m
GBPY, 2016

Revenue/Employee

26.5 k

Financial Leverage

1.1 x

GW Pharmaceuticals Market Value History

Traffic Overview of GW Pharmaceuticals

GW Pharmaceuticals News and Updates

UK has a future as a cannabis hub, says biotech company

The UK has the potential to become a world leader in drugs derived from the cannabis plant, according to a leading biotech firm. GW Pharmaceuticals chief executive, Justin Gover, told the Telegraph that the company is rapidly expanding its processing operations and hopes to get regulatory clearan…

A Japanese drug giant and a tiny New York biotech are teaming up in an unprecedented way

In drug development, the typical trajectory for a small biotech company is to develop a drug, then find a big-pharma partner to help fund trials and get the drug onto the market if it gets approved.  But a partnership announced today is bucking that trend. Japan's Takeda Ph…

Want Your Marijuana Startup to Succeed? Study Patent Law

If states legalize marijuana next week, startups will pounce on the new market—but first, they'll need to bone up on patent law. The post Want Your Marijuana Startup to Succeed? Study Patent Law appeared first on WIRED.

GW Pharmaceuticals and British Sugar sign cannabis plant deal

British Sugar – a subsidiary of Associated British Foods – has signed a deal to grow cannabis plants for GW Pharmaceuticals. The marijuana plants – which are of a non-psychoactive variety – are for use in GW’s experimental childhood epilepsy treatment called Epidiolex. The drug is derived from…
Show more

GW Pharmaceuticals Company Life and Culture

You may also be interested in